Rohokale R, Mane R, Malet L, Dessain S, Guo Z
J Org Chem. 2024; 90(1):877-888.
PMID: 39680867
PMC: 11756922.
DOI: 10.1021/acs.joc.4c02423.
Romano C, Jiang H, Tahvili S, Wei P, Keiding U, Clergeaud G
RSC Med Chem. 2024; 15(8):2718-2728.
PMID: 39149099
PMC: 11324045.
DOI: 10.1039/d4md00387j.
Imperio D, Valloni F, Caprioglio D, Minassi A, Casali E, Panza L
RSC Adv. 2024; 14(24):16778-16783.
PMID: 38784424
PMC: 11112678.
DOI: 10.1039/d4ra03011g.
Chen Y, Hung J, Jan F, Su Y, Hwu J, Yu A
Int J Mol Sci. 2022; 23(21).
PMID: 36362187
PMC: 9659121.
DOI: 10.3390/ijms232113403.
Li W, Guillaume J, Baqi Y, Wachsmann I, Gieselmann V, Van Calenbergh S
J Enzyme Inhib Med Chem. 2020; 35(1):1503-1512.
PMID: 32657203
PMC: 7470129.
DOI: 10.1080/14756366.2020.1791841.
Galactosylsphingamides: new α-GalCer analogues to probe the F'-pocket of CD1d.
Guillaume J, Wang J, Janssens J, Remesh S, Risseeuw M, Decruy T
Sci Rep. 2017; 7(1):4276.
PMID: 28655912
PMC: 5487351.
DOI: 10.1038/s41598-017-04461-7.
Total Synthesis of (-)-Lasonolide A.
Trost B, Stivala C, Fandrick D, Hull K, Huang A, Poock C
J Am Chem Soc. 2016; 138(36):11690-701.
PMID: 27548113
PMC: 5728428.
DOI: 10.1021/jacs.6b05127.
Divergent synthetic approach to 6''-modified α-GalCer analogues.
Pauwels N, Aspeslagh S, Vanhoenacker G, Sandra K, Yu E, Zajonc D
Org Biomol Chem. 2011; 9(24):8413-21.
PMID: 22042483
PMC: 3246390.
DOI: 10.1039/c1ob06235b.
The total synthesis of immunostimulant α-galactosylceramides from naturally configured α-galactoside raffinose.
Zhang Z, Zhao W, Wang B, Xia C, Zhang W, Wang P
Org Lett. 2011; 13(17):4530-3.
PMID: 21815670
PMC: 3398385.
DOI: 10.1021/ol201695n.
Novel galactosyl donor with 2-naphthylmethyl (NAP) as the non participating group at C-2 position: Efficient synthesis of alpha-galactosyl ceramide.
Khaja S, Kumar V, Ahmad M, Xue J, Matta K
Tetrahedron Lett. 2010; 51(33):4411-4414.
PMID: 20730042
PMC: 2923560.
DOI: 10.1016/j.tetlet.2010.06.071.
Synthesis and evaluation of amino-modified alpha-GalCer analogues.
Trappeniers M, Chofor R, Aspeslagh S, Li Y, Linclau B, Zajonc D
Org Lett. 2010; 12(13):2928-31.
PMID: 20518554
PMC: 2903208.
DOI: 10.1021/ol100934z.
Synthesis and biological activity of alpha-galactosyl ceramide KRN7000 and galactosyl (alpha1-->2) galactosyl ceramide.
Veerapen N, Brigl M, Garg S, Cerundolo V, Cox L, Brenner M
Bioorg Med Chem Lett. 2009; 19(15):4288-91.
PMID: 19502056
PMC: 2722241.
DOI: 10.1016/j.bmcl.2009.05.095.
Synthesis of all stereoisomers of KRN7000, the CD1d-binding NKT cell ligand.
Park J, Lee J, Ghosh S, Bricard G, Venkataswamy M, Porcelli S
Bioorg Med Chem Lett. 2008; 18(14):3906-9.
PMID: 18586489
PMC: 2754801.
DOI: 10.1016/j.bmcl.2008.06.036.
Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation.
Salio M, Speak A, Shepherd D, Polzella P, Illarionov P, Veerapen N
Proc Natl Acad Sci U S A. 2007; 104(51):20490-5.
PMID: 18077358
PMC: 2154458.
DOI: 10.1073/pnas.0710145104.
The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation.
McCarthy C, Shepherd D, Fleire S, Stronge V, Koch M, Illarionov P
J Exp Med. 2007; 204(5):1131-44.
PMID: 17485514
PMC: 2118584.
DOI: 10.1084/jem.20062342.
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.
Silk J, Hermans I, Gileadi U, Chong T, Shepherd D, Salio M
J Clin Invest. 2004; 114(12):1800-11.
PMID: 15599405
PMC: 535067.
DOI: 10.1172/JCI22046.